ANI Pharmaceuticals (ANIP)

[DEVJ]

Given the continued significant growth of ANI's portfolio (Corti drugs) as well as the possibility of the Libigel (A.K.A....?) deal, what would be considered a fair deal for ANI shareholders? $120, $150, $200?

Being a BPAX shareholder from well before the ANIP/BPAX union I would hope for at least a doubling of my BPAX investment, and that would require a deal of between $140-$150/share. I would like to believe ANIP management and/or BOD would give long-standing shareholders some consideration; however I also recognize they may be motivated by other interests.

Question for the board. Do Anip shareholders get any say in the terms of any potential deal? Will a proxy be issued relative to any potential deal?